Skip to main content
Sign In
 

About the Program


Program Learning Objectives 2019

The 2019 Aspen Lung Conference has the following Specific Aims / Objectives:

  1. To provide an international forum for leading basic, translational, and clinical researchers to exchange ideas regarding fundamental concepts regarding the pathogenesis and treatment of pulmonary hypertension (PH).
  2. To stimulate interactions between the fields of pulmonology, cardiology and oncology with the goal of identifying emerging, shared interests that may will lead to more efficient and productive research.
  3. To advance our understanding of clinical and molecular PH phenotypes/endotypes that predict risk or response in order to quickly translate preclinical findings to more effective, personalized therapies
  4. To challenge and thereby stimulate the scientific interests of trainees, attracting a new generation of junior investigators into ​ the field of PH pathobiology


Intended Audience  

Local/Regional/National/International Physicians/Clinicians (adult and pediatric)/Research Physician-Scientists in Pulmonary Sciences, Critical Care and Sleep Medicine/Primary Care Physicians/General Medicine Physicians/Public Health. 


The 62nd Annual Meeting, 2019

The Pulmonary Hypertension (PH) field has increasingly recognized that the pulmonary vascular pathology present in pulmonary hypertension (PH) has neoplastic-like features, including the identification of key shared  pathophysiology commonalities and now clinical trials of chemotherapy agents in patients with PH. The 2019 Thomas L. Petty Aspen Lung Conference will explore the common mechanisms found in neoplasia and PH, with the overall goal of translating our understanding of cellular metabolism, proliferation and signaling into more effective therapies for patients with PH. The title of the conference is Exploring New Therapeutic Pathways in Pulmonary Hypertension: Metabolism, Proliferation, and Personalized Medicine”.

T
he four days of the conference will integrate basic, translational, and clinical approaches while focusing on the following themes in PH: Cellular Metabolism, Hypoxia Signaling, Aberrant Cellular Proliferation and Personalized Medicine. We have identified 12 speakers who are outstanding scientists in their fields, who will present State of the Art lectures on these topics. Each of these presentations will be 35 minutes in duration, followed by 25 minutes for discussion to ensure a lively interaction which is a hallmark of this conference. Inclusion of trainees and junior faculty is emphasized by having two 15-minute oral abstracts following each State of the Art speaker, selected from submitted abstracts. There will be two evening poster sessions for further presentation opportunities by junior faculty and trainees. The final presentation is by a Conference Summarizer, who reviews the impact and common themes of the entire conference. The conference proceedings are subsequently published for widespread dissemination.

 In summary, the conference distinguishes itself from other conferences in the PH field by serving as a “think tankto actively discuss the current state of the field and identify the future directions for basic, translation and clinical research in PH. 


2019 ABSTRACT SUBMISSION OPEN

There are seven honorary lecturers: 

  • Parker B. Francis 
  • Roger S. Mitchell 
  • Giles F. Filley 
  • Thomas A. Neff 
  • Reuben M. Cherniack 
  • Thomas L. Petty 
  • Marvin I. Schwarz 

We look forward to your participation in the Thomas L. Petty Aspen Lung Conference, 62nd Annual Meeting and to a combination of outstanding science and great fun. We hope that you and your colleagues are able to join us. 

Americans with Disabilities Act Statement: Please indicate if you have any need for auxiliary aids or special assistance services.

Accreditation Statement 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Colorado School of Medicine and the Aspen Lung Conference.   The University of Colorado School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Colorado School of Medicine designates this live activity for a maximum of 12 AMA PRA Category 1 Credits.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

​​​